Journal
CELL HOST & MICROBE
Volume 26, Issue 6, Pages 712-713Publisher
CELL PRESS
DOI: 10.1016/j.chom.2019.11.006
Keywords
-
Categories
Funding
- National Institute of Allergy and Infectious Disease (NIAID) Collaborative Influenza Vaccine Innovation Centers (CIVIC) [75N93019C00051]
- NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) [HHSN272201400005C, HHSN272201400008C]
- NIAID [AI117287, AI128821, U19AI082724, U19AI109946, U19AI057266]
Ask authors/readers for more resources
Gilchuk et al. (2019) and Zhu et al. (2019) provide detailed structural information about epitopes on influenza virus N9 neuraminidase and characterize breadth, potency, mechanism of action, and in vivo protective effects of human antibodies targeting these epitopes. The findings highlight the importance of neuraminidase as a target for improved influenza virus vaccines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
